These remarks assume significance as the US continues to put India on its 'priority watch list' for intellectual property rights (IPR) through its Special 301 report that was released last month.
It was alleged that India's IPR regime is not in compliance with global norms, a charge India strongly contests at all forums.
Also Read
Asked about her views on whether the US would consider the new National IPR policy, announced by India, in preparing the next report, she said the decision which the US may take "does not worry me at all".
She said: "We do not give them a space because that (the report) is not done with mutual consent. I am not worried about that."
The developed countries have raised questions about section 3 (d) of the Indian Patent Act 1970 and compulsory licensing (CL), saying the norms restrict innovation.
The section does not allow patent to be granted to inventions involving new forms of a known substance unless it differs significantly in properties with regard to efficacy. In a way, it stops ever-greening of patents.
The minister said India is the country which provides affordable medicines to the whole world.
"Even many developed countries see India as the biggest source of bulk drugs and therefore, (it is) for us to see that our interests are safeguarded. Our intention on this are recorded and articulated well," she added.
The minister had recently said the US releases the Special 301 report to create pressure on countries to enhance IPR protection beyond the TRIPS (Trade-Related Aspects of Intellectual Property Rights) agreement.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)